Subscribe To

Price Alert Latest News Economic Calendar News

PEN / Penumbra's (PEN) CEO Adam Elsesser on Q1 2022 Results - Earnings Call Transcript

Penumbra, Inc. (NYSE:PEN ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Jee Hamlyn-Harris – Investor Relations Adam Elsesser – Chairman and Chief Executive Officer Maggie Yuen – Chief Financial Officer Jason Mills – Executive Vice President-Strategy Conference Call Participants Larry Biegelsen – Wells Fargo Robbie Marcus – JPMorgan Joanne Wuensch – Citi David Rescott – Truist Securities Ryan Zimmerman – BTIG Mike Matson – Needham & Company Pito Chickering – Deutsche Bank Operator Hello, my name is Stephanie and I'll be your conference operator today. At this time, I would like to welcome everyone to the Penumbra, Inc. First Quarter 2022 Earnings Conference Call. Read More

Demo Live Account See Partner Details

Content Topics

Penumbra

PEN

Adam

Elsesser

2022

Results

Earnings

Call

Penumbra s

Transcript

Stock

Posted: May 3 2022, 23:32

Author Name: Seeking Alpha

PEN News

By Zacks Investment Research
November 3, 2023

Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase

Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends.

By Seeking Alpha
November 2, 2023

Penumbra, Inc. (PEN) Q3 2023 Earnings Call Transcript

By Seeking Alpha
October 16, 2023

Penumbra: Appeal Improves, Just Not Appealing Yet

Penumbra's shares have nearly been cut in half after doubling in a six-month period, making investors cautious. The company has shown continued growth

By Zacks Investment Research
October 12, 2023

Here's Why You Should Hold on to Penumbra (PEN) Stock for Now

Investors are optimistic about Penumbra (PEN), driven by strong vascular and neuro businesses.

By Zacks Investment Research
September 22, 2023

Bull of the Day: Penumbra (PEN)

Penumbra ( PEN ) is the $10 billion innovator of neurovascular treatments for stroke using catheter aspiration technologies. After a solid beat-and-ra

By Zacks Investment Research
September 5, 2023

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

By Zacks Investment Research
August 2, 2023

Penumbra (PEN) Q2 Earnings Top Estimates, Sales View Raised

Penumbra's (PEN) U.S. thrombectomy records 50% year-over-year growth, while the international Vascular business sees relatively flat sales in the seco

By Seeking Alpha
August 1, 2023

Penumbra, Inc. (PEN) Q2 2023 Earnings Call Transcript

Penumbra, Inc. (NYSE:PEN ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Jee Hamlyn-Harris - IR Adam Elsesser - Chai

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.